What is William Blair's Estimate for AUTL FY2029 Earnings?

Key Points

• William Blair analyst M. Phipps has projected that Autolus Therapeutics will report earnings of $0.54 per share for FY2029, contrasting sharply with the consensus estimate of ($0.94) per share for the current year.
• In its most recent earnings report, Autolus Therapeutics exceeded expectations by posting ($0.18) earnings per share, surpassing the consensus estimate of ($0.24).
• Autolus Therapeutics has received positive ratings from multiple brokerages, with a consensus buy rating and a projected price target of $9.12 according to MarketBeat data.

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) - Research analysts at William Blair issued their FY2029 earnings per share estimates for shares of Autolus Therapeutics in a research report issued to clients and investors on Tuesday, August 12th. William Blair analyst M. Phipps expects that the company will post earnings of $0.54 per share for the year. The consensus estimate for Autolus Therapeutics' current full-year earnings is ($0.94) per share.

AUTL has been the topic of several other research reports. Needham & Company LLC reaffirmed a "buy" rating and set a $10.00 price target on shares of Autolus Therapeutics in a research note on Monday, July 21st. Wells Fargo & Company cut their price target on Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 13th. Finally, Wall Street Zen upgraded Autolus Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $9.12.

Autolus Therapeutics Trading Down 5.6%

Shares of AUTL traded down $0.1050 during trading hours on Thursday, hitting $1.7750. 1,686,794 shares of the stock traded hands, compared to its average volume of 1,878,696. Autolus Therapeutics has a 1-year low of $1.1050 and a 1-year high of $5.00. The firm has a market capitalization of $472.40 million, a PE ratio of -2.11 and a beta of 1.90. The business has a fifty day moving average of $2.31 and a 200-day moving average of $1.89.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.06. The business had revenue of $13.50 million during the quarter, compared to analyst estimates of $12.92 million.

Institutional Investors Weigh In On Autolus Therapeutics

Hedge funds have recently modified their holdings of the business. Jane Street Group LLC acquired a new stake in shares of Autolus Therapeutics during the fourth quarter worth about $26,000. Barclays PLC raised its position in shares of Autolus Therapeutics by 1,094.3% during the fourth quarter. Barclays PLC now owns 11,859 shares of the company's stock worth $28,000 after purchasing an additional 10,866 shares during the period. R Squared Ltd acquired a new stake in shares of Autolus Therapeutics during the second quarter worth about $50,000. Delaney Dennis R acquired a new stake in shares of Autolus Therapeutics during the second quarter worth about $55,000. Finally, Virtus ETF Advisers LLC raised its position in shares of Autolus Therapeutics by 29.9% during the fourth quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company's stock worth $62,000 after purchasing an additional 6,081 shares during the period. Institutional investors and hedge funds own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.